Stevanato Group to open US Technology Excellence Center in Boston

US TEC will support biopharma drug development throughout the lifecycle, helping them overcome the challenges of the container-closure system.

The new center will provide a full-service to support biopharmaceutical companies along their drug development journey, from the early phase to commercialization and lifecycle management, helping them to overcome the challenges of the container-closure system.

The technology and knowledge transfer from the Italian laboratory will be finalized later this year.

US TEC will support one of the most binding decisions for biopharma industry players: how to select the optimum glass container. Making the right choice during the early-stage of product development ensures two-fold compatibility: drug and container closure system, as well as container closure system integration into drug delivery devices.

"From its outset, the US TEC will advise on materials science, chemistry, and engineering performing many added value analytical tests focusing on container closure characterization as well as fill & finish development and optimization. In the second phase, we will be adding customized solutions dedicated to product development and functional testing of primary containers and drug delivery devices," said Paolo Patri, Stevanato Group Chief Technology Officer.

To support today's increasingly urgent need for treatments and vaccines related to COVID-19, Stevanato Group has deployed all its available assets to ensure the availability of state-of-the-art glass vials and syringes, plastics diagnostic consumables, equipment, and analytical testing.

"As pharma companies are under pressure to find more effective and safer treatments rapidly, more clinical trials take place, and new emerging therapies are developed and tested. Being in the US, we can offer timely solutions for robust product development for these therapies," said Abizer Harianawala, Site Leader at Stevanato Group's US TEC.